DOCSLIB.ORG

11 Nature America, Inc. All Rights Reserved

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PEOPLE Edison Liu (left) will leave his position as founding executive its board of directors. McMahon currently director of the Genome Institute of Singapore to become president serves as senior vice president of R&D and and CEO of The Jackson Laboratory (Bar Harbor, ME, USA) as of head of the oncology innovative medicines January 2012. He succeeds Rick Woychik, who departs for the unit for AstraZeneca. He has held various National Institute of Environmental Health Sciences where he will roles at Pfizer, Pharmacia, Sandoz and SUGEN. serve as deputy director. Formerly scientific director of the National Shiebler and Kessel will serve the remainder Cancer Institute’s division of clinical sciences, Liu was recruited of their current terms on the board but will to run GIS in 2001. He is also a two-term president of the Human not stand for reelection at OXiGENE’s annual Genome Organization. stockholder meeting this Fall. Leo Holt, chair of The Jackson Laboratory board of trustees said, “The Jackson Laboratory is a dynamic pivot point at the intersection of mammalian and Thrasos (Montreal) has announced the appoint- human genetics. [Ed Liu’s] talents run broad and deep, and his leadership is a great ment of Andreas Orfanos as chief medical offi- addition to the team that leads the search for tomorrow’s cures.” cer. Orfanos has over 25 years of experience in strategy development and executive and opera- Adrian Adams has been appointed chairman & Manufacturers of America and as deputy tional management in the healthcare industry, and CEO, and Andrew I. Koven has been assistant for the Asia-Pacific region in the Office as a principal in his own consulting firm and as named president and chief administrative offi- of the US Trade Representative. executive vice president, strategic planning and cer of Neurologix (Fort Lee, NJ, USA). Both scientific affairs at Neurochem. Adams and Koven also join the company’s XOMA (Berkeley, CA, USA) has announced board of directors, with Adams assuming the the resignation of Steve Engle as CEO, presi- Orion Genomics (St. role of chairman. Previously, Adams served as dent and chairman of the board. John Varian, Louis) has named Steven president and CEO of Inspire Pharmaceuticals a current board member, has been appointed W. Smith vice president and Sepracor. as interim CEO. He has previously served as of bioinformatics. Smith COO and CFO of Aryx Therapeutics and brings over 20 years of Acorda Therapeutics (Hawthorne, NY, USA) CFO of Genset. A search has been initiated for experience in the biotech has named Enrique J. Carrazana as chief a permanent CEO. In addition, W. Denman and bioinformatics field, medical officer, succeeding Thomas Wessel. Van Ness, XOMA’s lead independent director, most recently as head of Carrazana has over 20 years of experience has been named chairman of the board. consulting firm Genesmith Informatics. He in the pharma industry and clinical practice. previously served as vice president of bioinfor- Most recently, he was director of the Epilepsy Five Prime Therapeutics (S. San Francisco, CA, matics at NimbleGen Systems and has worked © 2011 Nature America, Inc. All rights reserved. All rights Inc. America, Nature © 2011 Center of Excellence at the Miami Veterans’ USA) has announced the election of Peder K. at Millipore, Genetics Computer Group and the Administration Hospital and associate profes- Jensen to its board of directors. Jensen most Harvard Genome Laboratory. sor of neurology at the University of Miami recently served as corporate senior vice presi- Miller School of Medicine. Prior to this, he held dent and general manager, R&D for Japan and Nikolaj Sørensen has been named chief com- various leadership roles at Novartis, including Asia/Pacific at Schering-Plough. He currently mercial officer for Orexo (Uppsala, Sweden). He vice president, global head of the established serves on the boards of Acorda Therapeutics previously worked at Pfizer where he was direc- medicines development franchise. and BioCryst Pharmaceuticals. tor and brand team leader for the company’s leading pain treatment product in Europe and Silence Therapeutics (London) has announced Robert Lollini has been appointed as CEO and Canada, as well as head of business development the appointment of Thomas Christély as CEO. a member of the board of directors of Myrexis and director of strategic planning for Pfizer AB. Christély is a 20-year veteran of corporate and (Salt Lake City, UT, USA). He joined the com- business development and finance, having pany in February 2009 as CFO and treasurer, Marc Tessier-Lavigne has been named to the served as CFO, COO and CEO of Atugen and rising to the position of interim president and board of directors of Agios Pharmaceuticals senior vice president and CFO at OXO Chemie. CEO. Previously, he was president and CEO (Cambridge, MA, USA). He is currently presi- He currently serves as nonexecutive chairman of of Iomed. Additionally, Myrexis has named dent of The Rockefeller University in New York the supervisory board of Müller-Spreer. He will Andrea Kendell as CFO. She had served as and formerly served as executive vice president be based at Silence’s facility in Berlin. vice president, finance and human resources for research and CSO at Genentech. since June 2010. The Biotechnology Industry Organization Immunovaccine (Halifax, Nova Scotia, (Washington) has selected Joseph Damond as OXiGENE (S. San Francisco, CA, USA) Canada) has appointed John J. Trizzino as senior vice president, international affairs. He has announced the appointment of Gerald CEO and a member of the board. He joins previously served as deputy vice president, inter- McMahon and the impending retirements Immunovaccine from Novavax, where he national affairs at the Pharmaceutical Research of William Shiebler and Mark Kessel from served as senior vice president. 950 VOLUME 29 NUMBER 10 OCTOBER 2011 NATURE BIOTECHNOLOGY.
Recommended publications
  • Biotech Investing 2020

    Biotech Investing 2020

    BIOTECH INVESTING 2020 Bill Cara www.billcara.com [email protected] 647-868-6013 JULY 20, 2020 A. Report Overview This Greenfield Capital (billcara.com) report on the Biotechnology industry is written by a registered investment consultant & portfolio manager, not by a scientist. Our objective is to provide education and information to investors who lack the tools to trade successfully in an industry made vitally important to the world by the coronavirus pandemic of 2020. If we want to live through this pandemic -- and future ones -- where it is possible that hundreds of millions of us could perish because of the lack of diagnostics, vaccines, and therapeutics, then as investors we should be keenly interested in the Biotech industry. News reports state that in just six and a half months, COVID-19, initially called SARS- CoV-2, has killed more people than the number of Americans who die each year from opioid overdose (46,000), traffic accidents (36,500), and gun violence (40,000) combined. But, currently, there is no vaccine for COVID-19, and the treatment options for patients with severe or life-threatening symptoms are limited. As the world struggles to contain the deadly virus, there are, fortunately, over 140 coronavirus vaccines in development. News is breaking every day. At the same time, however, many individuals who are trading in Biotech stocks remain woefully uninformed and are speculating wildly. Some Biotech stocks that have appreciated 100% or more in a few months on hopefulness may have trouble sustaining gains beyond the news peak. Still, for investors who study this industry, there are opportunities right now to buy Biotech stocks that will grow in price well into the future.
  • The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen

    The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen

    The Top 100 November, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. GPRO GoPro, Inc. Class A Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary UA Under Armour, Inc. Class A Consumer Discretionary CRC California Resources Corp Energy CRZO Carrizo Oil & Gas, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy FANG Diamondback Energy, Inc. Energy GST Gastar Exploration, Inc. Energy MPLX MPLX LP Energy RSPP RSP Permian, Inc. Energy SLCA U.S. Silica Holdings, Inc. Energy AAC AAC Holdings, Inc. Health Care ABEO Abeona Therapeutics, Inc. Health Care ACAD ACADIA Pharmaceuticals Inc. Health Care ADMP Adamis Pharmaceuticals Corporation Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADXS Advaxis, Inc. Health Care AIMT Aimmune Therapeutics Inc Health Care AKBA Akebia Therapeutics, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ARDM Aradigm Corporation Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care BCRX BioCryst Pharmaceuticals, Inc. Health Care BLUE bluebird bio, Inc. Health Care CARA Cara Therapeutics Inc Health Care CDNA CareDx, Inc. Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CFMS ConforMIS Inc Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CRMD CorMedix Inc. Health Care CSU Capital Senior Living Corporation Health Care DERM Dermira Inc Health Care DVAX Dynavax Technologies Corporation Health Care DXCM DexCom, Inc. Health Care EPZM Epizyme, Inc. Health Care FOLD Amicus Therapeutics, Inc. Health Care HRTX Heron Therapeutics Inc Health Care ICPT Intercept Pharmaceuticals, Inc.
  • Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm

    Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm

    Velliv noterede aktier i alt pr. 30-06-2021 ISIN Udstedelsesland Navn Markedsværdi (i DKK) US0378331005 US APPLE INC 1.677.392.695 US5949181045 US MICROSOFT CORP 1.463.792.732 US0231351067 US AMAZON.COM INC 1.383.643.996 DK0060534915 DK NOVO NORDISK A/S-B 1.195.448.146 US30303M1027 US FACEBOOK INC-CLASS A 1.169.094.867 US02079K3059 US ALPHABET INC-CL A 867.740.769 DK0010274414 DK DANSKE BANK A/S 761.684.457 DK0060079531 DK DSV PANALPINA A/S 629.313.827 US02079K1079 US ALPHABET INC-CL C 589.305.120 US90138F1021 US TWILIO INC - A 514.807.852 US57636Q1040 US MASTERCARD INC - A 490.766.560 US4781601046 US JOHNSON & JOHNSON 478.682.981 US70450Y1038 US PAYPAL HOLDINGS INC 471.592.728 DK0061539921 DK VESTAS WIND SYSTEMS A/S 441.187.698 US79466L3024 US SALESFORCE.COM INC 439.114.061 US01609W1027 US ALIBABA GROUP HOLDING-SP ADR 432.325.255 US8835561023 US THERMO FISHER SCIENTIFIC INC 430.036.612 US22788C1053 US CROWDSTRIKE HOLDINGS INC - A 400.408.622 KYG875721634 HK TENCENT HOLDINGS LTD 397.054.685 KR7005930003 KR SAMSUNG ELECTRONICS CO LTD 389.413.700 DK0060094928 DK ORSTED A/S 378.578.374 ES0109067019 ES AMADEUS IT GROUP SA 375.824.429 US46625H1005 US JPMORGAN CHASE & CO 375.282.618 US67066G1040 US NVIDIA CORP 357.034.119 US17275R1023 US CISCO SYSTEMS INC 348.160.692 DK0010244508 DK AP MOLLER-MAERSK A/S-B 339.783.859 US20030N1019 US COMCAST CORP-CLASS A 337.806.502 NL0010273215 NL ASML HOLDING NV 334.040.559 CH0012032048 CH ROCHE HOLDING AG-GENUSSCHEIN 325.008.200 KYG970081173 HK WUXI BIOLOGICS CAYMAN INC 321.300.236 US4370761029 US HOME DEPOT INC 317.083.124 US58933Y1055 US MERCK & CO.
  • EP Vantage Interview - Silence Hoping to Have Something to Shout About in 2009

    EP Vantage Interview - Silence Hoping to Have Something to Shout About in 2009

    December 22, 2008 EP Vantage Interview - Silence hoping to have something to shout about in 2009 Lisa Urquhart With its first product expected to go into the clinic potentially as early as January, Silence Therapeutics is hoping that 2009 will be year it has something to shout about and one that will reverse the alarming share price decline that has seen the company’s valuation slip from a high of over £170m in June 2007 to £21.6m today. Silence is one of a growing number of companies working in RNA interference (RNAi) and particularly short interfering RNA (siRNA), which work by selectively silencing or inactivating genes related to certain diseases. It is importantly one of only two companies that have composition of matter patent protection for their siRNA drugs. Speaking to EP Vantage, Iain Ross, chief executive of Silence, says: “It’s a big year coming up for us.” The group has spent most of the last 12 months strengthening its IP position, and next year comes the important move of the group’s lead candidate Atu027 into the clinic, an event Mr Ross says should take place in the first quarter of the year. Many expect it could be as soon as the end of January. Partnering focus What is less expected is the speed at which Mr Ross intends to partner the drug, which is being developed in solid tumours, with an emphasis on lung cancer. “We would be looking at doing something either at the end of 2009 or the beginning of 2010,” he says. Key to partnering discussions will be the drug demonstrating good safety data in a number of cancer patients, which could be the catalyst to starting talks with big pharma who have already started to ask about Atu027.
  • NASDAQ Stock Market

    NASDAQ Stock Market

    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
  • IQVIA Pharma Deals Half-Year Review of 2020

    IQVIA Pharma Deals Half-Year Review of 2020

    White Paper IQVIA Pharma Deals Half-Year Review of 2020 HEATHER CARTWRIGHT, Senior Analyst, Global Market Insights, IQVIA MICHELLE LIU, Analyst, Global Market Insights, IQVIA TASKIN AHMED, Manager, Global Market Insights, IQVIA Table of contents Introduction 1 Uncertainty and prudence cause M&A to stall 2 Licensing deal values continue to rise 5 Roche pips AstraZeneca to title of most active dealmaker 10 COVID-19 pandemic drives increase in R&D collaboration 11 Infectious diseases replace oncology as top therapeutic area for dealmaking 14 Outlook for H2 2020 15 About the authors 17 Introduction COVID-19 shakes up the dealmaking landscape H1 2020 was an unprecedented time for dealmaking in the life sciences sector. While the COVID-19 pandemic rapidly provoked a significant level of partnering activity amongst biopharma companies keen to expedite the development of vaccines or therapeutics to tackle the virus, it also acted as a brake on other types of dealmaking, most notably M&A which saw a sharp decline in activity as a result of uncertainty and operational disruption. Indeed, H1 2020 was notable for the absence of any US$5 B deals on the scale seen in previous years as companies instead focused their attentions on internal programs and potential COVID-19 solutions, opting only for a few asset-driven acquisitions. There was also plentiful capital available to allow biotech companies to stay independent, particularly those in the US. As a result, aggregate spending on M&A by life science companies plummeted to just US$19.1 B in the first 6 months of 2020.
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List

    CDER – Redi: Focus on CGMP & FDA Inspections – Participant List

    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP

    Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP

    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
  • Reduction in the Risk of Major Adverse Cardiovascular Events

    Reduction in the Risk of Major Adverse Cardiovascular Events

    Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial Gregory G. Schwartz1, Stephen J. Nicholls2, Henry N. Ginsberg3, Jan O. Johansson4, Kamyar Kalantar‐Zadeh5, Ewelina Kulikowski4, Peter P Toth6, Norman Wong4, Michael Sweeney4, Kausik K Ray7 On behalf of the BETonMACE Investigators 1Division of Cardiology, University of Colorado School of Medicine, Aurora, CO USA; 2Monash University Cardiovascular Research Center, Melbourne, Australia; 3Vagelos College of Physicians and Surgeons, Columbia University, New York, NY USA; 4Resverlogix Corp., Calgary, Alberta, Canada; 5University of California Irvine School of Medicine, Orange, CA USA; 6CGH Medical Center, Sterling, IL and Johns Hopkins University, Baltimore, MD USA; 7Imperial College Center for Cardiovascular Disease Prevention, London UK American Heart Association – 2020 Scientific Sessions November 2020 ClinicalTrials.gov: NCT02586155 Disclosures • The BETonMACE trial was funded by Resverlogix • Dr Schwartz reports research grants to the University of Colorado from Resverlogix, Sanofi, The Medicines Company, and Roche; and is coinventor of pending US patent 14/657192 (“Methods of Reducing Cardiovascular Risk”) assigned in full to the University of Colorado. • Dr. Nicholls reports grants from Resverlogix, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from
  • Unlocking the Potential of Gene Silencing for Everyone

    Unlocking the Potential of Gene Silencing for Everyone

    Corporate Presentation JP Morgan Conference January 2018 Forward looking statements The information contained in this presentation is being supplied and communicated to you on a Securities in the Company have not been, and will not be, registered under the United States confidential basis solely for your information and may not be reproduced, further distributed to Securities Act of 1933, as amended (the “Securities Act”), or qualified for sale under the law of any other person or published, in whole or in part, for any purpose. In accordance with the any state or other jurisdiction of the United States of America and may not be offered or sold in prohibition on market abuse contained in Part VIII of the Financial Services and Markets Act the United States of America except pursuant to an exemption from, or in a transaction not 2000 (as amended) (the “Act”): (i) you must not pass this information to any person; and (ii) subject to, the registration requirements of the Securities Act. Neither the United States you must not base any behaviour in relation to any securities or other Qualifying Investments Securities and Exchange Commission nor any securities regulatory body of any state or other (as that term is defined in the Act) which would amount to market abuse on such information jurisdiction of the United States of America, nor any securities regulatory body of any other until after it is made generally available. country or political subdivision thereof, has approved or disapproved of this presentation or the securities discussed herein or passed on the accuracy or adequacy of the contents of this This presentation is being communicated in the United Kingdom only to (a) persons who have presentation.
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01

    11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01

    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
  • GSK's Big Reveal

    GSK's Big Reveal

    3 August 2018 No. 3916 Scripscrip.pharmaintelligence.informa.com Pharma intelligence | informa at Genentech Inc. (Also see “GSK Bags Bar- ron As R&D Boss As Vallance Joins UK Govern- ment” - Scrip, 8 Nov, 2017.) With a budding early immuno-oncology pipeline, Walmsley clearly has her eye on establishing GSK as an important player in the space. The event in London was Barron’s first op- portunity to present his R&D strategy and coincided with the company’s second quar- ter sales and earnings release. “This is an ideal time to be thinking about reinventing R&D, because we are doing well. We are growing,” Barron said. PILLARS FOR INNOVATION Investors have been eager to hear from the R&D legend, but with few near-term catalysts or big changes to the late-stage pipeline, they may be underwhelmed by the update. Barron, meanwhile, is focused on deliver- GSK’s Big Reveal: ing scientific and cultural changes that will yield breakthroughs over the long-term. An R&D Overhaul Poised To Yield He talked about a time horizon of 2021 to 2026, and he talked more high-level, rather than specifics, about incentives needed to Long-Term Cultural Change drive innovation, the technologies that can JESSICA MERRILL [email protected] help improve clinical trial success, and cul- tural changes. He said science, technology laxoSmithKline PLC CEO Emma pharma R&D – is that investors will need to and culture are the three pillars needed to Walmsley may have spelled out the be patient to see GSK deliver on its promise drive innovation, and all three must be in Gbig pharma’s R&D turnaround plan of innovation.